Ticker Hub
RNXT — AI Analysis & Sentiment
5 recent AI-generated analyses for RNXT. Sentiment and confidence insights updated continuously.
RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer
FDA Orphan Drug Designation for oxaliplatin for pancreatic cancer provides significant regulatory and financial benefits for RenovoRx, strengthenin...
May 28, 2026RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting
RenovoRx's positive Phase III data validates its TAMP™ platform, enhancing the outlook for its lead pancreatic cancer therapy. This strengthens the...
May 26, 2026RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter
RenovoRx achieved record Q1 2026 revenue, significantly increasing quarter-over-quarter due to growing commercial adoption of its RenovoCath device...
May 14, 2026RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment
RenovoRx's achievement of a key Phase III enrollment milestone provides positive momentum for its lead cancer drug candidate. While clinical-stage ...
Mar 26, 2026RenovoRx Announces $10 Million at Market Private Placement
RenovoRx's $10 million private placement is a critical funding event that secures the company's operational runway. It enables acceleration of thei...
Mar 18, 2026